Table of contents

Electronic pages

European Society for Developmental Perinatal and Paediatric Pharmacology Congress, Leuven, 21-23 June 2017

• O-1 Dosing for two: placental transfer and fetal darunavir exposure (20 September, 2017)

  Greupink, Schalkwijk, Buaben, Freriksen, Colbers, Burger, Russel
• O-2 Population and developmental pharmacokinetic analysis to evaluate and optimise cefotaxime dosing regimen in neonates and young infants (20 September, 2017)

  Leroux, Roué, Gouyon, Biran, Zheng, Zhao, Jacqz-Aigrain
• O-3 Population pharmacokinetics and dosing optimisation of ceftriaxone in burn infants and children (20 September, 2017)

  Zhao
• O-4 Analysis of voriconazole monitoring data in children with onco-haematological diseases (20 September, 2017)

  LANCIA, Adam de Beaumais, Dalle
• O-5 Amikacin disposition and dosing recommendations in neonates with perinatal asphyxia treated with therapeutic hypothermia (amicool study) (20 September, 2017)

  Smits, Cristea, Knibbe, Kulo, Van Weissenbruch, Krekels, Allegaert
• O-6 Hyperfiltration in the paediatric intensive care unit (hypic) a pilot study (20 September, 2017)

  Van Der Heggen, Leenknegt, Roelandt, De Jaeger, Herck, Delanghe, Vande Walle, De Paepe, De Cock
• O-7 Vasopressin and terlipressin for refractory shock in neonates and children: systematic review meta-analysis and trial sequential analysis (20 September, 2017)

  Reem, Reif, Matok, Amichai, Hirsh Raccah, Paret
• O-8 The pharmacokinetics of fentanyl and its derivatives in children – a comprehensive review (20 September, 2017)

  Ziesenitz, Vaughns, Atkinson, Koch, Mikus, Van den Anker
• O-9 Paediatric pbpk modelling of propofol using the middle out approach (20 September, 2017)

  Michelet, Van Bocxlaer
• O-10 An observational study on plasma protein binding and target attainment of teicoplanin in critically ill children (20 September, 2017)

  De Cock, Wollaert, Desmet, McWhinney, De Jaeger, Vande Walle, De Paepe
• O-11 Maturation of human hepatic membrane transporter proteins in the first four months of life (20 September, 2017)

  Van Groen, Van De Steeg, Van Lipzig, Mooij, Wortelboer, Tibboel, Vaes, De Wildt
• O-12 The influence of patient covariates on insulin dose-requirements in children newly diagnosed with type 1 diabetes mellitus (20 September, 2017)

  Müller, Al-Sallami, Wheeler, Blackwell
• O-13 Factors impacting unbound vancomycin concentrations in neonates and young infants (20 September, 2017)

  Smits, Pauwels, Oyaert, Peersman, Spriet, Saegeman, Allegaert
• O-14 Neonatal cardiovascular and cerebral function after antenatal maternal exposure to magnesium sulfate (20 September, 2017)

  Kotidis, Sharp, Alfirevic, Weindling, Turner
• O-15 Population pharmacokinetic modelling of paracetamol and its two major metabolites after cardiac surgery in children with and without down syndrome (20 September, 2017)

  Mian, Valkenburg, Allegaert, Koch, Breatnach, Knibbe, Tibboel, Krekels
• O-16 Lean body weight based dosing achieves comparable systemic pantoprazole exposures for normal-weight and overweight/obese children (20 September, 2017)

  Shakhnovich, Abdel-Rahman, Friesen, Pearce, Gaedigk, Weigel, Leeder, Kearns
• O-17 Transplacental transport of paracetamol and its metabolites using the ex-vivo human placenta perfusion model (20 September, 2017)

  Conings, Tseke, Paulus, Qi, Amant, Annaert, Van Calsteren
• O-18 Clinical studies at-home: feasibility of data and sample collection in paediatric pain management after tonsillectomy (tomachi) (20 September, 2017)

  Von Niederhäusern, Saccilotto, Schädelin, Benkert, Summerer, Ziesenitz, Hammann, Bielicki, Pfister, Pauli-Magnus
• O-19 Incidence and risk factors of adverse events during immunosuppressive therapy after renal transplantation in children (20 September, 2017)

  LANCIA, Aurich, Ha, Deschênes
• O-20 Predictions of systemic drug exposure to gabapentin and tramadol following administration to children (20 September, 2017)

  Healy, Della Pasqua
• O-21 Use of antipsychotics in children and adolescents: a picture from the aritmo population-based european cohort study (20 September, 2017)

  Kaguelidou, Holstiege, Schink, Bezemer, Poluzzi, Mazzaglia, Pedersen, Sturkenboom, Trifirò
• O-22 Safe excipient exposure in neonates and small children – the seen project (20 September, 2017)

  Svinning, Valeur, Hertel, Engell Lundstrøm, Holst
• O-23 Ibuprofen in infants younger than 6 months: what is the efficacy and safety profile? (20 September, 2017)

  Ziesenitz, Zutter, Erb, Van den Anker
• O-24 Adrin 1 methodology study: adverse drug reactions in neonates: what are the best ways to evaluate suspected adverse drug reactions in neonates? (20 September, 2017)

  Roberts, Hawcutt, Turner
• O-25 Reduction of calculation errors with the dutch paediatric formulary’s web-based paediatric dosing calculator (20 September, 2017)

  Van der Zanden, De Hoog, Windster, De Wildt, Van der Sijs
• O-26 Folic acid during pregnancy and the risk of autism: a nested case-control study (20 September, 2017)

  Koren, Fono, Sharman Moser, Rotem, Davidovich, Chodik, Shalev
• O-27 Cross-sectional study evaluating pregnancy related use of vitamins and medication in belgium (previm-study) (20 September, 2017)

  Ceulemans, Allegaert, Van Calsteren
• O-28 Placental transfer of the immunosuppressive drug tacrolimus and its effects on placental function; relevance for renal transplant recipients? (20 September, 2017)

  Freriksen, Feyaerts, Van Den Broek, Van der Heijden, Van Drongelen, Russel, Van der Molen, Greupink
• O-29 Mag – médicaments administrés pendant la grossesse/drugs administered in pregnancy (20 September, 2017)

  Neyro, Elie, Valry, Mdard, Yves, Jacqz-Aigrain, Evelyne
• O-30 Levetiracetam therapeutic monitoring during pregnancy: an observational study (20 September, 2017)

  Shaniv
• O-31 Antiepileptic drug (aed) exposure in pregnancy and pregnancy outcome from national drug usage data (20 September, 2017)

  Richards, Reith, Smith, Stitely
• O-32 Prenatal exposure to acetamin-ophen and risk for attention defi-cit disorder (adhd): a systematic review and meta analysis (20 September, 2017)

  Reem, Reif, Levine, Matok
• O-33 Feasibility of a paediatric micro-dose study of [14c]midazolam to study the ontogeny of cyp3a-mediated drug metabolism (20 September, 2017)

  Van Groen, Mooij, Van Duijn, Knibbe, Allegaert, Windhorst, Van Rosmalen, Hendrikse, Tibboel, Vaes, De Wildt
• O-34 Neocord: mrna expression of cytochromes and transporters involved in drug metabolism at birth, using human umbilical cord blood (20 September, 2017)

  Neyro, Elie, Valry, Mdard, Yves, Jacqz-Aigrain, Evelyne
• O-35 A novel approach in paediatric drug design: the conventional pig as juvenile animal model (20 September, 2017)

  Millecam, Gasthuys, Devreese
• O-36 A human proximal tubular epithelial cell model to explore a knowledge gap on neonatal drug disposition (20 September, 2017)

  Raaijmakers, Reda, Van Dorst, Pauwels, Allegaert, Masereeuw, Van den Heuvel, Levtchenko, Arcolino
• O-37 Preventing aminoglycoside-induced nephrotoxicity using statins: an example of bench-to-bedside research (20 September, 2017)

  McWilliam, Antoine, Smyth, Pirmohamed
• O-38 The influence of body composi-tion on paediatric drug dosing (20 September, 2017)

  Al-Sallami
• O-39 Tacrolimus intra-patient variability is an independent factor associated with the need for liver biopsy in paediatric liver transplant recipients (20 September, 2017)

  Defrancq, De Wilde, Raes, De bruyne, Prytula
• O-40 Novel tailored training concept to facilitate successful study conduct and optimise recruitment in paediatric clinical trials (20 September, 2017)

  Burckhardt, Ciplea, Kleine, Ablonczy, Breur, Dalinghaus, Van der Meulen, Klingmann, Spatenkova, Swoboda, Bajcetic, Keatley-Clarke, Laeer, Lagler
• O-41 Pharmacogenomic studies of corticosteroid effectiveness in paediatric asthma: a systematic review (20 September, 2017)

  Hawcutt, Thomas
• O-42 Eptri – european paediatric translational research infra-structure to promote technolo-gy-driven paediatric research (20 September, 2017)

  Bonifazi, Lupo, Ruggieri, Intini, Giaquinto, Migliaccio, Neubert, CK Wong, Macheras, Lavitrano, Kleanthous, Jacqz-Aigrain, De Wildt, Tuleu, Turner, Migdal, Clavero, Torres, Ceci
• PP-2 Ethanol content in registered paediatric preparations: address the excess (20 September, 2017)

  Berlin, Shaniv, Mendelson Mastey, Ainbinder, Schwartzberg, Berkovitch
• PP-4 Diagnostic and therapeu-tic approaches in children with asthma in lombardy region, italy (20 September, 2017)

  Clavenna, Casartelli, Cartabia, Bonati
• PP-6 Integration and validation of the ex vivo human placenta perfusion model (20 September, 2017)

  Conings, Amant, Annaert, Van Calsteren
• PP-8 Transition instead of transfer for drug treatment in adolescent diabetes type 1 (20 September, 2017)

  Deters, Läer, Obarcanin
• PP-10 Adverse drug reactions in hospitalised children in an aca-demic hospital in the netherlands (20 September, 2017)

  Dittrich, Te Loo, Draaisma
• PP-12 Mag – medicaments administres pendant la grossesse/drugs administered in pregnancy (20 September, 2017)

  Elie, Neyro, Jacqz-Aigrain
• PP-14 Substandard prescription of drugs in a population of overweight and obese children. an observational retrospective cohort study (20 September, 2017)

  Gade, Christensen, Dalhoff, Holm, Holst
• PP-16 In search of an algorithm for calculation of antibiotic use in a children´s hospital (20 September, 2017)

  Gober
• PP-18 Ranitidine-induced thrombocytopenia in a neonate-a case report and review of literature (20 September, 2017)

  Hoste, George
• PP-20 The use of physical activ-ity trackers in clinical research – an overview (20 September, 2017)

  Lambrechtse, Ziesenitz, Cohen, Van Den Anker, Bos
• PP-22 Adherence to labelling guidelines, the case of fluoroquinolones. results of a retrospective multicenter drug utilisation study (20 September, 2017)

  Meesters, Mauel, Dhont, Vande Walle, De Bruyne
• PP-24 Consent in neonatal research: a delphi survey interrogating parents of preterm newborns and healthcare professionals (20 September, 2017)

  Neyro, Elie, Thiele, Jacqz-Aigrain
• PP-26 Neocord: mrna expression of cytochromes and transporters involved in drug metabolism at birth, using human umbilical cord blood (20 September, 2017)

  Neyro, Elie, Médard, Jacqz-Aigrain
• PP-28 Unlicensed and off-label medication use in a paediatric and neonatal intensive care units at a single medical centre: no change over a decade (20 September, 2017)

  Berkovitch, Abu-Kishk, Heyman, Nir
• PP-30 Clinical utility and safety of ganoderma lucidum extract in acute lymphoblastic leukaemia as a adjuvant therapy: a case report (20 September, 2017)

  Peire, Fernandez de Ana, Sanchez Luces, Rodriguez Blanco, Simon
• PP-32 Do plasma amino acid levels reflect arginine metabolism in parenteral nutrition (pn) dependent very preterm infants? (20 September, 2017)

  PREMAKUMAR
• PP-34 Adverse drug reactions in neonates: comparing retrospective spontaneous yellow card reports to prospectively collected reports (20 September, 2017)

  Roberts, Hawcutt, Turner
• PP-36 Therapeutic indications for use of extemporaneous glucocorticoid formulations in children – the glufic study (20 September, 2017)

  Schmidt, Haslund-Krog, Jørgensen, Lambrechtse
• PP-38 Getting paediatric medicines on-label – scoping the needs for paediatric formulation of old medicines (20 September, 2017)

  ‘t Jong, Gilpin, Litalien
• PP-40 Prenatal antibiotic exposure and childhood chronic disease: a population-based study (20 September, 2017)

  ‘t Jong, Delara, Monchka, Mahmud
• PP-42 Evaluation of rhigf-1/rhigfbp-3 to establish and maintain physiological intrauterine serum igf-1 levels early after birth in extremely preterm infants (20 September, 2017)

  Turner, Hallberg, Ingrid, Hellström, Ley, Mangili, Tocoian, Barton, Chung
• PP-44 Developing a paediatric drug formulary for the netherlands (20 September, 2017)

  Van der Zanden, De Wildt, Liem, Offringa, De Hoog
• PP-46 Voriconazole dosing strategies in young children: challenges and recommendations (20 September, 2017)

  Witjes, Zandvliet, Dijkstra, Kors, Abbink, Smetsers, Swart, Sombogaard, Wilhelm
• PP-48 Population pharmacokinetics and dosing optimisation of cefathiamidine in infants and children (20 September, 2017)

  Zhao
• PP-50 Population pharmacokinetics and dosing optimisation of latamoxef in neonates (20 September, 2017)

  Zhao
• PP-52 Getting paediatric medicines on-label – scoping the needs for paediatric formulation of old medicines (20 September, 2017)

  Andréa Gilpin, Geert ‘t Jong, Catherine Litalien
• PP-54 Prenatal antibiotic exposure and childhood asthma: a population-based study (20 September, 2017)

  ‘t Jong, Loewen, Monchka
• PP-1 The prematch study: an effort to quantify the impact of preterm birth on cardiovascular and renal health (20 September, 2017)

  Allegaert, Staessen
• PP-3 Standard of care for children with heart failure in europe: results of a survey and a subsequent delphi questionnaire (20 September, 2017)

  Makowski, Castro Diez, Dalinghaus, DeWildt, Van der Meulen, Bajcetic, Jovanovic, Male, Ablonczy, Szatmári, Schwender, Läer
• PP-5 Prescription of biosimilar somatropin in the italian paediatric population (20 September, 2017)

  Clavenna, Pepino, Cartabia, Bonati
• PP-7 The safe-pedrug initiative: an opportunity for academia to close the gap (20 September, 2017)

  De Bruyne, Vande Walle, The SAFE-PEDRUG consortium
• PP-9 Participating in paediatric drug research: identifying the burden (20 September, 2017)

  Dewolf, Amza, Christiaens, De Bruyne, De Cock, Vande Walle
• PP-11 Comparing completion rates of paediatric versus adult randomised controlled trials: a cross-sectional study (20 September, 2017)

  Kaguelidou, Dufetelle
• PP-13 An analysis of the applications for a paediatric investigation plan (pip) for indications in uro-nephrology (20 September, 2017)

  Feneberg, Sosare, Marx
• PP-15 The conventional pig as pk/pd/toxicity model for the pediatric subpopulation: development of urine and blood sampling strat-egies in growing piglets (20 September, 2017)

  Gasthuys, Van Bergen, Schauvliege, Millecam, Croubels, Devreese
• PP-17 Intravenous paracetamol in neonates: safety, ethanol-drug interactions and efficacy – protocol of the parashute trial (20 September, 2017)

  Haslund-Krog, Hertel, Dalhoff, Van den Anker, Brink Henriksen, Holst
• PP-19 Quantification of gait in children with mitochondrial disease: a validation study (20 September, 2017)

  Koene, Imelda, Kim, Maaike, Lonneke, Mirian, Niki, Jan
• PP-21 Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum (20 September, 2017)

  Maleskic Kapo, Kulo, Smits, Van de Velde, Van Calsteren, De Hoon, Verbesselt, Deprest, Allegaert
• PP-23 Under pressure: minocycline-induced pseudotumor cerebri. a case report and literature review (20 September, 2017)

  Müeller, Gilardoni, Capone Mori, Thali, Bucher, Zöhrer, Koehler
• PP-25 Drug use during pregnancy: a systematic review (20 September, 2017)

  Neyro, Elie, Jacqz-Aigrain
• PP-27 Survey of children and young people’s perceptions of clinical research (20 September, 2017)

  Ni, Li, Qi, Shu
• PP-29 Growth hormone dosing in obese children (20 September, 2017)

  Peak, Hawcutt, Bellis, Price, McCoy, Newland, Blair
• PP-31 Kinetically guided dosing of vancomycin in critical ill neonates and young infants treated for sepsis (20 September, 2017)

  Pokorna, Síma, Cerná, Allegaert, Tibboel
• PP-33 Codeine and tramadol use in a paediatric population in new zealand (20 September, 2017)

  Reith, Simpson, Medlicott, Smith
• PP-35 Clinical features and therapeutic options in children with neurofibromatosis 1: a single centre experience (20 September, 2017)

  Samardzic, Milenkovic, Nikolic, Ivancevic, Hencic, Jancic
• PP-37 Developing paediatric antimicrobial doses for the new zealand formulary for children (20 September, 2017)

  Simpson, Young, Herd, Ferguson, Broughton, Tilyard, Reith
• PP-39 Prenatal antibiotic exposure and childhood asthma: a population-based study (20 September, 2017)

  ‘t Jong, Loewen, Monchka, Mahmud
• PP-41 Risk assessment for compatibility of rhigf-1/rhigfbp-3 with commonly administered neonatal intravenous medications based on an experimental model (20 September, 2017)

  Turner, Bandekar, Barton, Hsiao, Jochim, Mangum, McPherson, Tenjarla, Salamat-Miller
• PP-43 Pharmacogenomics factors relating to ibuprofen and acute kidney injury in paediatric patients: a systematic review (20 September, 2017)

  Unsworth, Hawcutt
• PP-45 Gentamicin exposure in neonates according to swiss neo-natal intensive care dosing regi-mens and international guidelines (20 September, 2017)

  Van Donge
• PP-47 Off-label use of tacrolimus in children with henoch-schonlein purpura nephritis: efficacy and safety (20 September, 2017)

  Zhao, Zhang, Hao, Li, Dong, Dong, Jacqz-Aigrain, Shi
• PP-49 Population pharmacokinetics and dosing optimisation of cefoperazone in children (20 September, 2017)

  Zhao
• PP-51 Metamizole-induced agranulocytosis in an adolescent treated for chronic headache (20 September, 2017)

  Ziesenitz, Trachsel, Van den Anker